SG10201707786QA - Use Of Semaphorin-4D Binding Molecules For Treating Neurodegenerative Disorders - Google Patents

Use Of Semaphorin-4D Binding Molecules For Treating Neurodegenerative Disorders

Info

Publication number
SG10201707786QA
SG10201707786QA SG10201707786QA SG10201707786QA SG10201707786QA SG 10201707786Q A SG10201707786Q A SG 10201707786QA SG 10201707786Q A SG10201707786Q A SG 10201707786QA SG 10201707786Q A SG10201707786Q A SG 10201707786QA SG 10201707786Q A SG10201707786Q A SG 10201707786QA
Authority
SG
Singapore
Prior art keywords
semaphorin
binding molecules
neurodegenerative disorders
treating neurodegenerative
treating
Prior art date
Application number
SG10201707786QA
Other languages
English (en)
Inventor
Ernest S Smith
Maurice Zauderer
William J Bowers
Alan Jonason
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of SG10201707786QA publication Critical patent/SG10201707786QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201707786QA 2013-10-21 2014-10-21 Use Of Semaphorin-4D Binding Molecules For Treating Neurodegenerative Disorders SG10201707786QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361893814P 2013-10-21 2013-10-21
US201461979384P 2014-04-14 2014-04-14
US201462012805P 2014-06-16 2014-06-16

Publications (1)

Publication Number Publication Date
SG10201707786QA true SG10201707786QA (en) 2017-10-30

Family

ID=52826380

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707786QA SG10201707786QA (en) 2013-10-21 2014-10-21 Use Of Semaphorin-4D Binding Molecules For Treating Neurodegenerative Disorders
SG11201603167YA SG11201603167YA (en) 2013-10-21 2014-10-21 Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201603167YA SG11201603167YA (en) 2013-10-21 2014-10-21 Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Country Status (19)

Country Link
US (4) US9598495B2 (fr)
EP (2) EP3639853A1 (fr)
JP (2) JP6461944B2 (fr)
KR (4) KR20230159633A (fr)
CN (2) CN106029093B (fr)
AU (3) AU2014340210B2 (fr)
BR (1) BR112016009047B1 (fr)
CA (2) CA2927841C (fr)
DK (1) DK3060252T3 (fr)
EA (1) EA033072B1 (fr)
ES (1) ES2773961T3 (fr)
IL (3) IL275720B (fr)
MX (2) MX2016005050A (fr)
NZ (1) NZ630892A (fr)
PL (1) PL3060252T3 (fr)
PT (1) PT3060252T (fr)
SG (2) SG10201707786QA (fr)
WO (1) WO2015061330A1 (fr)
ZA (1) ZA201602686B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8496938B2 (en) 2009-05-08 2013-07-30 Vaccinex, Inc. Anti-CD100 neutralizing neutralizing antibodies and methods of using the same
KR101999872B1 (ko) 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2014116982A2 (fr) * 2013-01-25 2014-07-31 Brandeis University Procédés de modulation de la formation et fonction de synapse inhibitrice gabaergique
KR20210104166A (ko) 2013-06-25 2021-08-24 백시넥스 인코포레이티드 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
PL3445397T3 (pl) 2016-04-22 2023-03-20 Vaccinex, Inc. Integralne białko błonowe prezentowane na powierzchni zewnątrzkomórkowej formy wirionu z otoczką
CA3032512A1 (fr) 2016-08-02 2018-02-08 Vaccinex, Inc. Procedes ameliores de production de bibliotheques de polynucleotides dans le virus de la vaccine/cellules eucaryotes
JP7084689B2 (ja) * 2016-12-08 2022-06-15 公益財団法人東京都医学総合研究所 脳組織の異常を伴う非ヒト動物の作製方法およびその利用
BR112019017367A2 (pt) * 2017-02-22 2020-04-14 Vaccinex Inc detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias
DK3600419T5 (en) 2017-03-20 2024-05-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
MX2019013110A (es) 2017-05-05 2019-12-16 Vaccinex Inc Anticuerpo anti-semaforina 4d humano.
CN109410218B (zh) * 2018-10-08 2020-08-11 百度在线网络技术（北京）有限公司 用于生成车辆损伤信息的方法和装置
EP3693380A1 (fr) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Double inhibition de plexin-b1 et plexin-b2
AU2021297152A1 (en) 2020-06-25 2023-02-02 The Sydney Children's Hospitals Network Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
JPWO2022137964A1 (fr) * 2020-12-23 2022-06-30
CA3231551A1 (fr) * 2021-09-27 2023-03-30 Maurice Zauderer Profilage predictif de resultats pour l'utilisation d'une molecule de liaison anti-semaphorine-4d pour traiter des troubles neurodegeneratifs
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (fr) 1997-04-07 1998-10-15 Genentech, Inc. Anticorps anti-vegf
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP2001516226A (ja) 1997-04-11 2001-09-25 デンドレオン コーポレイション 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法
EP0892047A3 (fr) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Semaphorine L humaine et murine
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
JP4451987B2 (ja) 1998-11-10 2010-04-14 ユニバーシティー オブ ロチェスター 標的抗原に特異的なｔ細胞ならびにこれに基づく方法およびワクチン
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
WO2002102854A2 (fr) 2001-06-20 2002-12-27 Morphosys Ag Anticorps bloquant l'activation d'une tyrosine kinase de type proteine receptrice, procedes permettant l'identification de cet anticorps et utilisations de celui-ci
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (fr) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Function de la sémaphorine CD100 dans la myélination
EP1513554B9 (fr) 2002-05-30 2011-11-09 Macrogenics, Inc. Proteines de liaison a cd16a et leur utilisation pour le traitement de troubles immunitaires
EP1442749A1 (fr) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'un anticorps anti-CD100 pour le traitement et le diagnostic d'une maladie inflammatoire du système nerveux central
KR20160114727A (ko) 2003-05-30 2016-10-05 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
AU2005267720B2 (en) 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
EP1871484A2 (fr) 2005-04-07 2008-01-02 Chiron Corporation Gene sema4d utilise dans le diagnostic, la detection et le traitement du cancer
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
WO2008100995A1 (fr) 2007-02-14 2008-08-21 Vaccinex, Inc. Anticorps humains anti-cd100
TW200934512A (en) 2008-01-10 2009-08-16 Genentech Inc PLEXIND1 agonists and their use
US8496938B2 (en) 2009-05-08 2013-07-30 Vaccinex, Inc. Anti-CD100 neutralizing neutralizing antibodies and methods of using the same
EP2429585B1 (fr) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Immunothérapie par vaccin
CA2802376A1 (fr) 2010-06-14 2011-12-22 Vaccinex, Inc. Anticorps anti-vegf et utilisations de ceux-ci
DK2711023T3 (en) 2011-05-13 2017-10-16 Nat Univ Corp Tokyo Medical & Dental Univ osteogenesis
KR101999872B1 (ko) * 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
KR20210104166A (ko) 2013-06-25 2021-08-24 백시넥스 인코포레이티드 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
PL3445397T3 (pl) 2016-04-22 2023-03-20 Vaccinex, Inc. Integralne białko błonowe prezentowane na powierzchni zewnątrzkomórkowej formy wirionu z otoczką
CA3032512A1 (fr) 2016-08-02 2018-02-08 Vaccinex, Inc. Procedes ameliores de production de bibliotheques de polynucleotides dans le virus de la vaccine/cellules eucaryotes
BR112019017367A2 (pt) 2017-02-22 2020-04-14 Vaccinex Inc detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias

Also Published As

Publication number Publication date
EP3060252A4 (fr) 2017-06-07
US10385136B2 (en) 2019-08-20
EP3060252B1 (fr) 2019-12-11
AU2019257379A1 (en) 2019-11-14
US9249227B2 (en) 2016-02-02
US20170198053A1 (en) 2017-07-13
PT3060252T (pt) 2020-03-04
KR102308493B1 (ko) 2021-10-07
IL275720A (en) 2020-08-31
KR102602502B1 (ko) 2023-11-14
CA3193983A1 (fr) 2015-04-30
CA2927841A1 (fr) 2015-04-30
US20190322757A1 (en) 2019-10-24
EP3639853A1 (fr) 2020-04-22
IL245089A0 (en) 2016-06-30
US20150110800A1 (en) 2015-04-23
KR20230159633A (ko) 2023-11-21
US10800853B2 (en) 2020-10-13
IL295045A (en) 2022-09-01
AU2014340210A1 (en) 2016-05-05
JP2019059786A (ja) 2019-04-18
JP6875363B2 (ja) 2021-05-26
AU2014340210B2 (en) 2019-08-08
DK3060252T3 (da) 2020-03-16
KR20160065981A (ko) 2016-06-09
IL295045B2 (en) 2024-04-01
WO2015061330A1 (fr) 2015-04-30
IL245089B (en) 2020-10-29
CN106029093A (zh) 2016-10-12
KR20220110853A (ko) 2022-08-09
ES2773961T3 (es) 2020-07-15
JP2017502920A (ja) 2017-01-26
CN106029093B (zh) 2023-03-28
SG11201603167YA (en) 2016-05-30
KR20210118246A (ko) 2021-09-29
JP6461944B2 (ja) 2019-01-30
BR112016009047A2 (pt) 2017-09-19
EA033072B1 (ru) 2019-08-30
BR112016009047B1 (pt) 2024-02-06
IL295045B1 (en) 2023-12-01
PL3060252T3 (pl) 2020-05-18
AU2021202095A1 (en) 2021-05-06
US9598495B2 (en) 2017-03-21
NZ630892A (en) 2016-03-31
AU2019257379B2 (en) 2021-04-01
ZA201602686B (en) 2020-11-25
EA201690813A1 (ru) 2016-08-31
IL275720B (en) 2022-09-01
AU2021202095B2 (en) 2023-11-02
CA2927841C (fr) 2023-05-23
MX2020009260A (es) 2020-10-01
CN116966293A (zh) 2023-10-31
MX2016005050A (es) 2016-08-17
US20150353641A1 (en) 2015-12-10
AU2021202095B9 (en) 2023-11-09
EP3060252A1 (fr) 2016-08-31

Similar Documents

Publication Publication Date Title
IL275720A (en) Use of molecules that bind semphorin-D4 for the treatment of neurodegenerative disorders
ZA201602577B (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
EP2852388A4 (fr) Composés et méthodes d'utilisation de ceux-ci pour traiter des troubles neurodégénératifs
IL243419A0 (en) Biomarkers for the treatment of neoplastic disorders using androgen-targeted therapies
HK1224182A1 (zh) 用於治療神經疾病的包含托拉塞米和巴氯芬的組合物
HK1214553A1 (zh) 用於治療神經退行性疾病的拉喹莫德和普利多匹定
EP2970317A4 (fr) Composés pyrimido-diazépinone et procédés de traitement de troubles
HK1210593A1 (en) Tetracycline compounds for treating neurodegenerative disorders
EP2953950A4 (fr) Compositions et méthodes de traitement de maladies neurodégénératives
HK1213576A1 (zh) 用於治療成骨不全的方法
GB201312279D0 (en) Neurodegenerative disorders
EP2976094A4 (fr) Méthodes de traitement de troubles métaboliques
IL245541A0 (en) New methods for the treatment of neurodegenerative diseases
IL276431A (en) Treatment of the brain disorders and related symptoms
HK1220453A1 (zh) 治療運動障礙和相關病症的方法
SG11201605292UA (en) Solubilisation of uv filters
HK1224220A1 (zh) 治療神經退化性失調的方法
EP2968550A4 (fr) Compositions et procédés pour le traitement de troubles liés à l'angiogenèse
AU2013903509A0 (en) Device for treating respiratory disorders